Crowdonomics
Starpax Biopharma Inc.

Reg A+ · Equity · Feb 2023

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$232.6K / $25M max
1% of ceiling
Investors
—
—
Estimated pre-money
$471.9M
—

Financials disclosed in this offering

FY2021 · hover for source
$0
−$3.5M
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$0
Cost of goods sold
$3,405,000
Net income
-$3,520,000
Balance sheet
Cash
$4,780,000
Accounts receivable
$0
Total assets
$27,253,000
Long-term debt
$3,875,000
Total liabilities
$8,290,000
Other
Headcount
40

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Sep 19, 2024
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  2. Aug 15, 2023
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$471.9M
Price / share$6.25
Shares offered4,000,000

Estimated, not stated: $6.25 × 75,500,000 securities outstanding.

Offering details

Target—
Max$25,000,000
Min investment—
OpenedFeb 9, 2023
Deadline—
ClosedApr 18, 2025
Days active799

Links & provenance

Source: SEC EDGAR
0001960682-23-000001
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.